Market Access | Getting therapies in patients' hands

News

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

European study shows inequality in access to new medicines

Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.

News

SCOTUS won't hear pharma's IRA complaints

The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.

News

AZ gets first okay for new hypertension drug baxdrostat

AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.

News

After refusing to resign, CDER head Høeg is fired

The turmoil at the FDA continues with the news that Tracy Beth Høeg has been fired as acting head of CDER, to be replaced by Michael Davis.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

QuintilesIMS Rare Diseases webinar _16x9 holding slide_170405

Sponsored

When small becomes big: orphan medicines, advances, access a...

Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.

Debates & Insight

PHOENIX Group Pharmacist webinar _16x9 holding slide_170327

Sponsored

Unlocking the value of pharmacists to reach the right patien...

Pharmacists are highly trained healthcare professionals who have a deep understanding of medicines and daily contact with patients and consumers, putting them in a unique position in terms of being able to maximise the benefits that patients get from their medicines. However, healthcare systems and pharmaceutical companies frequently overlook this potential.

Debates & Insight

Sponsored

Approval and access: overcoming the final hurdle of drug dev...

2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater col

News

Bayer gets swift review for Kerendia in type 1 diabetes

FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.

News

European study shows inequality in access to new medicines

Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Views & Analysis

Market Access

Innovation beyond invention will bring novel medicines to Eu...

Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.

Market Access

pharma commercialisation concept - hcp and laptop and metrics

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.

Deep Dive

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

Market Access

The expanding role of early-phase trials in modern drug deve...

Market Access

Market Access 2026

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and en

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Market Access

pharmaphorum podcast Episode 210 - Neal Masia

Smoothing a contract pathway through uncertainty: In convers...

Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.

Video

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Market Access

Partner Content

Measuring Patient Engagement Summit Europe

The World’s Only Patient Engagement Measurement Summit is coming to Europe!

Market Access

Partner Content

The Inaugural Market Access for CNS Therapeutics Summit Has ...

The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Market Access

Partner Content

Targeted Therapies Partnering & Licensing Summit Asia

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnersh

Bayer gets swift review for Kerendia in type 1 diabetes

European study shows inequality in access to new medicines

SCOTUS won't hear pharma's IRA complaints

AZ gets first okay for new hypertension drug baxdrostat

After refusing to resign, CDER head Høeg is fired

When small becomes big: orphan medicines, advances, access a...

Unlocking the value of pharmacists to reach the right patien...

Approval and access: overcoming the final hurdle of drug dev...

Bayer gets swift review for Kerendia in type 1 diabetes

European study shows inequality in access to new medicines

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

VuuAI and Amiculum partner to transform content engagement i...

Innovation beyond invention will bring novel medicines to Eu...

Views from Asembia: EVERSANA's take on outsourcing, AI, and ...

Can direct-to-employer models close the GLP-1 obesity care g...

The expanding role of early-phase trials in modern drug deve...

Market Access 2026

Innovative Medicines Fund and the opportunity for ICSs to mo...

Medical Informatics and Rare Disease: a bridge between two w...

ICSs - an opportunity to improve Patient & Market Access at ...

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Smoothing a contract pathway through uncertainty: In convers...

Making direct-to-patient work, with Matt Wadyka

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Consolidating data strategy for global success: Insights fro...

Life Sciences Industry Report 2025

Navigating Routes to Commercial Excellence in Cell and Gene ...

Pricing & Market Access Outlook 2015/2016 Edition

Targeted Therapies Partnering & Licensing Summit Asia

Measuring Patient Engagement Summit Europe

The Inaugural Market Access for CNS Therapeutics Summit Has ...

Innovative contracting in Europe – a Trojan horse?

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

VuuAI and Amiculum partner to transform content engagement i...

Targeted Therapies Partnering & Licensing Summit Asia

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks